Pharsight

1. Implanon patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP18182632A	2021-06-16	Consilient Health Limited	Granted and Under Opposition
EP06707783A	2019-04-11	Holme Patent A/S	Granted and Under Opposition
EP06707776A	2017-05-10	ELKINGTON AND FIFE LLP	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8888745	ORGANON	Applicator for inserting an implant	Aug, 2026 (2 years from now)
US10821277	ORGANON	Kit for and method of assembling an applicator for inserting an implant	May, 2027 (3 years from now)
US8722037	ORGANON	X-ray visible drug delivery device	Sep, 2027 (4 years from now)
US9757552	ORGANON	Applicator for inserting an implant	Jul, 2030 (6 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

Strength	Dosage	Availability
68MG/IMPLANT	IMPLANT;IMPLANTATION	Prescription

IMPLANON family patents

2. Singulair patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02801836A	2008-11-05	Hexal AG	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007830	ORGANON	Granule formation	Oct, 2022 (11 months ago)

Drugs and Companies using MONTELUKAST SODIUM ingredient

Market Authorisation Date: 26 July, 2002

Treatment: NA

Dosage: GRANULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4 mg	17 Oct, 2008	1	03 Aug, 2012	03 Aug, 2012	Extinguished

Strength	Dosage	Availability
EQ 4MG BASE/PACKET	GRANULE;ORAL	Prescription

SINGULAIR family patents

3. Zetia patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02770534A	2009-07-14	TEVA PHARMACEUTICAL INDUSTRIES LTD.	Opposition procedure closed
EP02707500A	2008-02-22	EGIS Gyógyszergyár Nyrt	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7030106	ORGANON	Sterol absorption inhibitor compositions	Jan, 2022 (1 year, 8 months ago)
US7030106 (Pediatric)	ORGANON	Sterol absorption inhibitor compositions	Jul, 2022 (1 year, 2 months ago)
US7612058	ORGANON	Methods for inhibiting sterol absorption	Oct, 2025 (2 years from now)
US7612058 (Pediatric)	ORGANON	Methods for inhibiting sterol absorption	Apr, 2026 (2 years from now)

Drugs and Companies using EZETIMIBE ingredient

Market Authorisation Date: 25 October, 2002

Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of el...

Dosage: TABLET;ORAL